THE LONG-TERM ONCOLOGICAL RESULTS OF RADICAL PROSTATECTOMY IN PATIENTS WITH A MAXIMUM FOLLOW-UP OF UP TO 15 YEARS, WHO MEET THE ERSPC (PRIAS) CRITERIA FOR ACTIVE SURVEILLANCE
https://doi.org/10.17650/1726-9776-2013-9-3-55-58
Abstract
No consensus on how to select patients is one of the factors restricting the wide acceptance of active surveillance (AS). The frequency of unfavorable histological findings and long-term overall and relapse-free survival rates were studied in 152 patients who met the ERSPC [European Randomized Study of Screening for Prostate Cancer] (PRIAS) criteria for AS and had undergone retropubic prostatectomy (RPE) in the period 1997 to 2010. Negative histological characteristics were found in more than 10 % of the patients, with the median postoperative followup of 67 months biochemical recurrence developed in 3 (2 %) patients. Five- and ten-year relapse-free survival rates were 97 and 88.2 %, respectively. Histological and long-term oncological results after RPE are suboptimal in the patients meeting the PRIAS criteria. There is a need for additional studies of the safety and efficiency of AS under conditions of Russian public health.
About the Authors
E. I. Veliev
Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian, Moscow
Russian Federation
Russian Federation
Department of Urology and Surgical Andrology
O. B. Loran
Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian, Moscow
Russian Federation
Russian Federation
Department of Urology and Surgical Andrology
E. A. Sokolov
Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian, Moscow
Russian Federation
Russian Federation
Department of Urology and Surgical Andrology
References
1. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481–8.
2. Jemal A., Siegel R., Xu J. et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
3. Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации. Экспер и клин урол 2011;2–3:6–7.
4. Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
5. Cooperberg M.R., Carroll P.R., Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669–76.
6. Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.
7. Cooperberg M.R., Cowan J.E., Hilton J.F. et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011;29:228–34.
8. Satkunasivam R., Kulkarni G.S., Zlotta A.R. et al. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol 2013;190:91–6.
9. van den Bergh R.C., Vasarainen H., van der Poel H.G. et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 2010;105:956–62.
10. Draisma G., Boer R., Otto S.J. et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.
11. Schroder F.H., Hugosson J., Roobol M.J. et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.
12. Tosoian J.J., Trock B.J., Landis P. et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–90.
13. van As N.J., Norman A.R., Thomas K. et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297–305.
14. Pinheiro L., Farinha R., Silva T. et al. Pathological features after radical prostatectomy for low risk prostate cancer candidates to active surveillance. Eur Urol Suppl 2007;6(2):279.
15. Mitsuzuka K., Narita S., Koie T. et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria. BJU Int 2013;111(6):914–20.
16. Suardi N., Capitanio U., Briganti A. et al. Outcome of patients potentially suitable for active surveillance undergoing radical prostatectomy as first treatment choice. J Urol Suppl 2010;183(4):673.
17. Watts S.D., Leydon G., Ridout A.J. et al. The prevalence of depression and anxiety in men undergoing active surveillance for prostate cancer. Eur Urol Suppl 2013;12:275.
18. Klotz L. Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 2013;64:37–40.
19. Fujita K., Landis P., McNeil B.K. et al. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664–29.
20. Coffin G., Ploussard G., Cortesse A. et al. Does initial prostate functional MRI impact on treatment choice for patients on active surveillance? Eur Urol Suppl 2012;11:e765.
Review
For citations:
Veliev E.I., Loran O.B., Sokolov E.A. THE LONG-TERM ONCOLOGICAL RESULTS OF RADICAL PROSTATECTOMY IN PATIENTS WITH A MAXIMUM FOLLOW-UP OF UP TO 15 YEARS, WHO MEET THE ERSPC (PRIAS) CRITERIA FOR ACTIVE SURVEILLANCE. Cancer Urology. 2013;9(3):55-58. (In Russ.) https://doi.org/10.17650/1726-9776-2013-9-3-55-58
Views:
725
Email this article 